STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Qureshy Z, Li H, Zeng Y, Rivera J, et al. Clin Cancer Res 2022 Aug 5. pii: 707467. doi: 10.1158/1078-0432.CCR-22-0744.

Read + Share

Amedeo Smart

Independent Medical Education

Qureshy Z, Li H, Zeng Y, Rivera J, et al. STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Clin Cancer Res 2022 Aug 5. pii: 707467. doi: 10.1158/1078-0432.CCR-22-0744.
PMID: 35929989